Michaelson JS - Search Results

1

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.

Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, Marklin M, Heitmann JS, Kauer J, Osburg L, Zekri L, Bühring HJ, Mueller S, Hörner S, Baeuerle PA, Michaelson JS, Jung G, Salih HR. Mehta NK, et al. Among authors: michaelson js. J Immunother Cancer. 2022 Mar;10(3):e003882. doi: 10.1136/jitc-2021-003882. J Immunother Cancer. 2022. PMID: 35288466 Free PMC article.

2

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM. Michaelson JS, et al. MAbs. 2009 Mar-Apr;1(2):128-41. doi: 10.4161/mabs.1.2.7631. Epub 2009 Mar 11. MAbs. 2009. PMID: 20061822 Free PMC article.

3

Development of an Fn14 agonistic antibody as an anti-tumor agent.

Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, Wille L, Schneider P, Wortham K, Burkly LC, Hsu YM, Joseph IB. Michaelson JS, et al. MAbs. 2011 Jul-Aug;3(4):362-75. doi: 10.4161/mabs.3.4.16090. Epub 2011 Jul 1. MAbs. 2011. PMID: 21697654 Free PMC article.

4

Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM. Miller BR, et al. Among authors: michaelson js. Protein Eng Des Sel. 2010 Jul;23(7):549-57. doi: 10.1093/protein/gzq028. Epub 2010 May 10. Protein Eng Des Sel. 2010. PMID: 20457695

5

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.

Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB. Michaelson JS, et al. Cancer Biol Ther. 2012 Jul;13(9):812-21. doi: 10.4161/cbt.20564. Epub 2012 Jun 6. Cancer Biol Ther. 2012. PMID: 22669574 Free article.

6

TWEAK signals through JAK-STAT to induce tumor cell apoptosis.

Chapman MS, Wu L, Amatucci A, Ho SN, Michaelson JS. Chapman MS, et al. Among authors: michaelson js. Cytokine. 2013 Jan;61(1):210-7. doi: 10.1016/j.cyto.2012.09.020. Epub 2012 Oct 27. Cytokine. 2013. PMID: 23107828

7

Pathological activation of canonical nuclear-factor κB by synergy of tumor necrosis factor α and TNF-like weak inducer of apoptosis in mouse acute colitis.

Dohi T, Kawashima R, Kawamura YI, Otsubo T, Hagiwara T, Amatucci A, Michaelson J, Burkly LC. Dohi T, et al. Cytokine. 2014 Sep;69(1):14-21. doi: 10.1016/j.cyto.2014.05.001. Epub 2014 May 27. Cytokine. 2014. PMID: 25022957

8

Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.

Michaelson JS, Burkly LC. Michaelson JS, et al. Results Probl Cell Differ. 2009;49:145-60. doi: 10.1007/400_2008_18. Results Probl Cell Differ. 2009. PMID: 19513634 Review.

9

Tweak induces mammary epithelial branching morphogenesis.

Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, Hsu YM, Burkly LC. Michaelson JS, et al. Oncogene. 2005 Apr 14;24(16):2613-24. doi: 10.1038/sj.onc.1208208. Oncogene. 2005. PMID: 15735761

10

Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Michaelson JS, et al. J Autoimmun. 2012 Sep;39(3):130-42. doi: 10.1016/j.jaut.2012.05.003. Epub 2012 Jun 22. J Autoimmun. 2012. PMID: 22727560 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters